TABLE 1.
Clinical traits between SLC2A3 high- and low-expression groups.
| Characteristic | Levels | Low expression of SLC2A3 | High expression of SLC2A3 | p |
|---|---|---|---|---|
| N | 187 | 188 | ||
| Age, n (%) | ≤65 | 88 (23.7%) | 76 (20.5%) | 0.312 |
| >65 | 99 (26.7%) | 108 (29.1%) | ||
| Gender, n (%) | Female | 66 (17.6%) | 68 (18.1%) | 0.945 |
| Male | 121 (32.3%) | 120 (32%) | ||
| T stage, n (%) | T1 | 16 (4.4%) | 3 (0.8%) | 0.002 |
| T2 | 40 (10.9%) | 40 (10.9%) | ||
| T3 | 92 (25.1%) | 76 (20.7%) | ||
| T4 | 39 (10.6%) | 61 (16.6%) | ||
| N stage, n (%) | N0 | 58 (16.2%) | 53 (14.8%) | 0.577 |
| N1 | 50 (14%) | 47 (13.2%) | ||
| N2 | 40 (11.2%) | 35 (9.8%) | ||
| N3 | 32 (9%) | 42 (11.8%) | ||
| M stage, n (%) | M0 | 167 (47%) | 163 (45.9%) | 0.965 |
| M1 | 12 (3.4%) | 13 (3.7%) | ||
| Pathologic stage, n (%) | Stage I | 32 (9.1%) | 21 (6%) | 0.256 |
| Stage II | 59 (16.8%) | 52 (14.8%) | ||
| Stage III | 71 (20.2%) | 79 (22.4%) | ||
| Stage IV | 16 (4.5%) | 22 (6.2%) | ||
| Residual tumor, n (%) | R0 | 152 (46.2%) | 146 (44.4%) | 0.616 |
| R1 | 6 (1.8%) | 9 (2.7%) | ||
| R2 | 7 (2.1%) | 9 (2.7%) | ||
| Histologic grade, n (%) | G1 | 6 (1.6%) | 4 (1.1%) | 0.082 |
| G2 | 77 (21%) | 60 (16.4%) | ||
| G3 | 98 (26.8%) | 121 (33.1%) |